Similar phenomena were also observed in a clinical trial of LUXTURNA, a commercially available gene therapy drug for RPE65-related IRDs, where one participant who showed high-titer neutralizing antibodies prior to treatment did, in fact, benefit from the treatment.27 These findings suggest that in ocular gene therapy trials with subretinal administration, it may be advisable to limit patients according to the baseline measured titer of AAV neutralizing antibodies and that the current titer of 1:1000 may, in fact, be too high and should be reduced appropriately. This evidence concerns the gene RPE65 and respiratory distress syndrome in premature infants.